Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC

AIM: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for EGFR mutation-positive NSCLC. MATERIALS & METHODS: Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for T790M-mediat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lung Cancer Manag
Main Authors: Imamura, Fumio, Inoue, Takako, Kunimasa, Kei, Kubota, Aki, Kuhara, Hanako, Tamiya, Motohiro, Nishino, Kazumi, Kimura, Madoka, Kuno, Kika, Kawachi, Hayato, Kumagai, Toru
Formato: Artigo
Idioma:Inglês
Publicado em: Future Medicine Ltd 2020
Assuntos:
Short Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7186852/
https://ncbi.nlm.nih.gov/pubmed/32346403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2020-0005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados